Luisa Bertin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Luisa Bertin has a total of 263 co-authors. Here are the top co-authors by number of shared publications:
- Edoardo Savarino
Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
51 shared publications - Fabiana Zingone
Department of Surgery, Oncology, Gastroenterology, University of Padua, Padua, Italy
24 shared publications - Brigida Barberio
Gastroenterology Unit, Azienda Ospedale—Università Padova, 35128 Padua, Italy
21 shared publications - Daria Maniero
Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
10 shared publications - Sonia Facchin
Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, 35128 Padua, Italy
9 shared publications - Erica Bonazzi
Department of Surgery, Oncology and Gastroenterology, University of Padua, 35124 Padua, Italy
7 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (11) , 2477
Ultra-Processed Foods in Inflammatory Bowel Disease and Irritable Bowel Syndrome: Epidemiology, the Intestinal Microenvironment and Implications for Dietary Management
Ultra-processed foods (UPFs) provide more than half of daily energy intake in several high-income countries, and their consumption is increasing worldwide. Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are chronic gastrointestinal conditions whose burden has grown alongside industrialized dietary patterns. Here, we summarize the epidemiological, mechanistic and clinical evidence linking UPF consumption to both conditions. Most prospective cohorts and meta-analyses associate higher UPF intake with incident Crohn’s disease, whereas associations with ulcerative colitis are weaker and inconsistent. In IBS, observational studies, including a large prospective cohort, suggest a modest, dose-dependent association with risk, although data are limited and the diagnostic criteria have recently changed with Rome V. Mechanistically, both disorders may converge on the intestinal microenvironment: in experimental models, emulsifiers alter microbial composition and metabolism, the mucus layer, epithelial barrier integrity and mucosal immune activation, and non-nutritive sweeteners alter microbial composition and epithelial barrier function, although human data are limited and causality has not been established. We also discuss IBS-like symptoms in quiescent IBD, dietary management in both conditions, and the main knowledge gaps, including exposure assessment, residual confounding and the need for adequately powered intervention trials.
- 30 October 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (11) , 2477
Open AccessUltra-Processed Foods in Inflammatory Bowel Disease and Irritable Bowel Syndrome: Epidemiology, the Intestinal Microenvironment and Implications for Dietary Management
Ultra-processed foods (UPFs) provide more than half of daily energy intake in several high-income countries, and their consumption is increasing worldwide. Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are chronic gastrointestinal conditions whose burden has grown alongside industrialized dietary patterns. Here, we summarize the epidemiological, mechanistic and clinical evidence linking UPF consumption to both conditions. Most prospective cohorts and meta-analyses associate higher UPF intake with incident Crohn’s disease, whereas associations with ulcerative colitis are weaker and inconsistent. In IBS, observational studies, including a large prospective cohort, suggest a modest, dose-dependent association with risk, although data are limited and the diagnostic criteria have recently changed with Rome V. Mechanistically, both disorders may converge on the intestinal microenvironment: in experimental models, emulsifiers alter microbial composition and metabolism, the mucus layer, epithelial barrier integrity and mucosal immune activation, and non-nutritive sweeteners alter microbial composition and epithelial barrier function, although human data are limited and causality has not been established. We also discuss IBS-like symptoms in quiescent IBD, dietary management in both conditions, and the main knowledge gaps, including exposure assessment, residual confounding and the need for adequately powered intervention trials.
- Open Access
- 3 October 2026
- Published by MDPI AG in Gastroenterology Insights
- Vol. 17 (4) , 57
Impact of Obesity and Its Treatment on Inflammatory Bowel Disease Outcomes: A Narrative Review
Obesity is a chronic inflammatory condition whose rising incidence has turned it into a global epidemic, a trend that also affects people living with inflammatory bowel diseases (IBD). Recent epidemiological data indicate that roughly 25 to 40% of patients with IBD are overweight and that 15 to 40% have obesity. Obesity can contribute to the pathogenesis of IBD and acts as a negative prognostic factor for disease course, response to pharmacological treatment, hospitalizations, post-surgical complications, and quality of life. Overall, the rate of adverse events related to the intestinal disease is higher in patients with obesity, and early data suggest that exposure to weight-loss interventions is associated with more favourable disease outcomes. The relationship between obesity and IBD is complex and involves systemic inflammation, increased production of proinflammatory cytokines, greater intestinal permeability, microbiota alterations, dietary patterns, and hormonal changes. Weight loss interventions, including lifestyle modification, pharmacological treatment, and bariatric surgery, appear to influence IBD-related outcomes, with growing attention to the emerging role of glucagon-like peptide-1 (GLP-1) receptor agonists. Several questions remain open and could guide future research, since a full understanding of the interplay between IBD and obesity is crucial for effective personalized treatment.
- 3 October 2026
- Published by MDPI AG in Gastroenterology Insights
- Vol. 17 (4) , 57
Open AccessImpact of Obesity and Its Treatment on Inflammatory Bowel Disease Outcomes: A Narrative Review
Obesity is a chronic inflammatory condition whose rising incidence has turned it into a global epidemic, a trend that also affects people living with inflammatory bowel diseases (IBD). Recent epidemiological data indicate that roughly 25 to 40% of patients with IBD are overweight and that 15 to 40% have obesity. Obesity can contribute to the pathogenesis of IBD and acts as a negative prognostic factor for disease course, response to pharmacological treatment, hospitalizations, post-surgical complications, and quality of life. Overall, the rate of adverse events related to the intestinal disease is higher in patients with obesity, and early data suggest that exposure to weight-loss interventions is associated with more favourable disease outcomes. The relationship between obesity and IBD is complex and involves systemic inflammation, increased production of proinflammatory cytokines, greater intestinal permeability, microbiota alterations, dietary patterns, and hormonal changes. Weight loss interventions, including lifestyle modification, pharmacological treatment, and bariatric surgery, appear to influence IBD-related outcomes, with growing attention to the emerging role of glucagon-like peptide-1 (GLP-1) receptor agonists. Several questions remain open and could guide future research, since a full understanding of the interplay between IBD and obesity is crucial for effective personalized treatment.
- Open Access
Dietary and Parenteral Nutritional Management of Short Bowel Syndrome with Intestinal Failure in Adults: A Narrative Review
Short bowel syndrome (SBS) is the leading cause of chronic intestinal failure in adults, arising when the residual small bowel can no longer absorb the macronutrients, water, and electrolytes needed to sustain health without intravenous supplementation. Its management is, at its core, a nutritional problem. This narrative review summarises and critically appraises current evidence and guideline recommendations on the two pillars of that management: dietary (oral/enteral) therapy and parenteral nutritional support. We frame both around the two variables that dominate clinical behaviour, namely residual intestinal anatomy and the phase of intestinal adaptation, and translate them into anatomy-tailored dietary strategies, rational fluid and electrolyte replacement, micronutrient surveillance, and the composition, delivery, and complications of (home) parenteral nutrition. We also position the pharmacological adjuncts, culminating in glucagon-like peptide-2 (GLP-2) analogues, within a stepwise strategy to reduce parenteral support dependence. The goal throughout is a practical, physiology-anchored approach that maximises enteral autonomy and quality of life while preventing the metabolic, hepatic and catheter-related complications of long-term intravenous feeding. The literature was identified through structured but non-systematic searches of PubMed/MEDLINE, Embase and the Cochrane Library, and the nature of the evidence supporting each recommendation, ranging from randomised trials to expert consensus, is indicated throughout the text.
Open AccessDietary and Parenteral Nutritional Management of Short Bowel Syndrome with Intestinal Failure in Adults: A Narrative Review
Short bowel syndrome (SBS) is the leading cause of chronic intestinal failure in adults, arising when the residual small bowel can no longer absorb the macronutrients, water, and electrolytes needed to sustain health without intravenous supplementation. Its management is, at its core, a nutritional problem. This narrative review summarises and critically appraises current evidence and guideline recommendations on the two pillars of that management: dietary (oral/enteral) therapy and parenteral nutritional support. We frame both around the two variables that dominate clinical behaviour, namely residual intestinal anatomy and the phase of intestinal adaptation, and translate them into anatomy-tailored dietary strategies, rational fluid and electrolyte replacement, micronutrient surveillance, and the composition, delivery, and complications of (home) parenteral nutrition. We also position the pharmacological adjuncts, culminating in glucagon-like peptide-2 (GLP-2) analogues, within a stepwise strategy to reduce parenteral support dependence. The goal throughout is a practical, physiology-anchored approach that maximises enteral autonomy and quality of life while preventing the metabolic, hepatic and catheter-related complications of long-term intravenous feeding. The literature was identified through structured but non-systematic searches of PubMed/MEDLINE, Embase and the Cochrane Library, and the nature of the evidence supporting each recommendation, ranging from randomised trials to expert consensus, is indicated throughout the text.
- Open Access
- 21 September 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (11) , 1365-1366
Monitoring Crohn's disease beyond endoscopy: what does healing mean when biomarkers, imaging and histology disagree?
- 21 September 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (11) , 1365-1366
Open AccessMonitoring Crohn's disease beyond endoscopy: what does healing mean when biomarkers, imaging and histology disagree?
- Open Access
The Role of Diet in Functional Dyspepsia
Functional dyspepsia (FD) is a disorder of gut–brain interaction affecting approximately 7% of the global population under Rome IV criteria, characterised by postprandial fullness, early satiation, epigastric pain, and/or epigastric burning in the absence of identifiable organic disease. Meal ingestion is the dominant symptom trigger in the majority of patients, yet the relationship between diet and FD is bidirectional: dietary exposures drive symptoms through established pathophysiological mechanisms, while FD itself can promote maladaptive eating behaviours and progressive dietary restriction with nutritional and psychological consequences. The pathophysiological substrate linking diet to symptom generation encompasses impaired gastric accommodation and emptying, visceral hypersensitivity to mechanical and chemical stimuli, low-grade duodenal mucosal immune activation and epithelial barrier impairment, alterations of the small intestinal microbiota, and gut–brain axis dysregulation. Dietary fat is the macronutrient most consistently implicated, acting through cholecystokinin-mediated chemosensory and mechanosensory pathways. Cross-sectional population data suggest that a high protein intake may also be associated with epigastric pain, although this association did not persist after multivariable adjustment, while the evidence linking total carbohydrate intake to symptoms remains sparse and inconsistent, so that no recommendation on total carbohydrate intake can currently be made. Cognitive factors, including learned food beliefs, expectancy, and nocebo effects, further modulate symptom perception independently of actual nutrient content. Among dietary patterns, Mediterranean-style eating offers the most coherent mechanistic rationale and the strongest observational support, while a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) shows selective benefit in patients with postprandial distress syndrome features or prominent bloating. Common triggers including spicy foods, coffee, and alcohol show heterogeneous evidence driven by individual sensitivity rather than dose-related effects. Nutritional concerns are substantial: clinically significant weight loss affects approximately 35% of tertiary-care patients, and nearly 40% screen positive for avoidant/restrictive food intake behaviour using validated screening tools. Dietary management should therefore be individualised, nutritionally adequate, and integrated within a broader biopsychosocial framework, with screening for disordered eating before any elimination strategy is initiated.
Open AccessThe Role of Diet in Functional Dyspepsia
Functional dyspepsia (FD) is a disorder of gut–brain interaction affecting approximately 7% of the global population under Rome IV criteria, characterised by postprandial fullness, early satiation, epigastric pain, and/or epigastric burning in the absence of identifiable organic disease. Meal ingestion is the dominant symptom trigger in the majority of patients, yet the relationship between diet and FD is bidirectional: dietary exposures drive symptoms through established pathophysiological mechanisms, while FD itself can promote maladaptive eating behaviours and progressive dietary restriction with nutritional and psychological consequences. The pathophysiological substrate linking diet to symptom generation encompasses impaired gastric accommodation and emptying, visceral hypersensitivity to mechanical and chemical stimuli, low-grade duodenal mucosal immune activation and epithelial barrier impairment, alterations of the small intestinal microbiota, and gut–brain axis dysregulation. Dietary fat is the macronutrient most consistently implicated, acting through cholecystokinin-mediated chemosensory and mechanosensory pathways. Cross-sectional population data suggest that a high protein intake may also be associated with epigastric pain, although this association did not persist after multivariable adjustment, while the evidence linking total carbohydrate intake to symptoms remains sparse and inconsistent, so that no recommendation on total carbohydrate intake can currently be made. Cognitive factors, including learned food beliefs, expectancy, and nocebo effects, further modulate symptom perception independently of actual nutrient content. Among dietary patterns, Mediterranean-style eating offers the most coherent mechanistic rationale and the strongest observational support, while a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) shows selective benefit in patients with postprandial distress syndrome features or prominent bloating. Common triggers including spicy foods, coffee, and alcohol show heterogeneous evidence driven by individual sensitivity rather than dose-related effects. Nutritional concerns are substantial: clinically significant weight loss affects approximately 35% of tertiary-care patients, and nearly 40% screen positive for avoidant/restrictive food intake behaviour using validated screening tools. Dietary management should therefore be individualised, nutritionally adequate, and integrated within a broader biopsychosocial framework, with screening for disordered eating before any elimination strategy is initiated.
- Open Access
Dietary Approaches in Eosinophilic Esophagitis
Eosinophilic esophagitis (EoE) is a chronic, immune-mediated, non-IgE-mediated food allergy and a leading cause of dysphagia and food impaction in adults, with rising prevalence worldwide. Diagnosis requires ≥15 eosinophils per high-power field on esophageal biopsy after exclusion of other causes of gastrointestinal eosinophilia. Food allergens, principally milk, wheat, eggs, legumes and seafood, drive the inflammatory process, and treatment options include proton pump inhibitors, topical corticosteroids, biologic agents and endoscopic dilation for stricturing disease. Among these, dietary therapy is the only approach that removes the causative trigger rather than suppressing the inflammatory response, making drug-free, sustained remission achievable. Elemental diets achieve the highest histological remission rates but are poorly tolerated in practice; empiric elimination following a step-up strategy, starting with one or two foods and escalating in the absence of response, is more practical for most adults. Conventional allergy testing cannot reliably identify food triggers in EoE and is not recommended for this purpose. Reintroduction of the trigger food leads to relapse, making long-term adherence essential, and not all patients are suitable candidates: repeated endoscopy, dietary restriction, quality of life impact and the risk of avoidant restrictive food intake disorder (ARFID) are barriers that must be weighed before recommending this approach. This review summarizes the available dietary approaches in adult and adolescent EoE, covering empiric elimination strategies and their efficacy, allergy test-directed diets, patient selection, the role of diet alongside other treatments, and nutritional adequacy and adherence.
Open AccessDietary Approaches in Eosinophilic Esophagitis
Eosinophilic esophagitis (EoE) is a chronic, immune-mediated, non-IgE-mediated food allergy and a leading cause of dysphagia and food impaction in adults, with rising prevalence worldwide. Diagnosis requires ≥15 eosinophils per high-power field on esophageal biopsy after exclusion of other causes of gastrointestinal eosinophilia. Food allergens, principally milk, wheat, eggs, legumes and seafood, drive the inflammatory process, and treatment options include proton pump inhibitors, topical corticosteroids, biologic agents and endoscopic dilation for stricturing disease. Among these, dietary therapy is the only approach that removes the causative trigger rather than suppressing the inflammatory response, making drug-free, sustained remission achievable. Elemental diets achieve the highest histological remission rates but are poorly tolerated in practice; empiric elimination following a step-up strategy, starting with one or two foods and escalating in the absence of response, is more practical for most adults. Conventional allergy testing cannot reliably identify food triggers in EoE and is not recommended for this purpose. Reintroduction of the trigger food leads to relapse, making long-term adherence essential, and not all patients are suitable candidates: repeated endoscopy, dietary restriction, quality of life impact and the risk of avoidant restrictive food intake disorder (ARFID) are barriers that must be weighed before recommending this approach. This review summarizes the available dietary approaches in adult and adolescent EoE, covering empiric elimination strategies and their efficacy, allergy test-directed diets, patient selection, the role of diet alongside other treatments, and nutritional adequacy and adherence.
- Open Access
- 27 August 2026
- Published by MDPI AG in Preprints.org
Dietary and Parenteral Nutritional Management of Short Bowel Syndrome with Intestinal Failure in Adults
Short bowel syndrome (SBS) is the leading cause of chronic intestinal failure in adults, arising when the residual small bowel can no longer absorb the macronutrients, water and electrolytes needed to sustain health without intravenous supplementation. Its management is, at its core, a nutritional problem. This review synthesises current evidence and guideline recommendations on the two pillars of that management: dietary (oral/enteral) therapy and parenteral nutritional support. We frame both around the two variables that dominate clinical behaviour, namely residual intestinal anatomy and the phase of intestinal adaptation, and translate them into anatomy-tailored dietary strategies, rational fluid and electrolyte replacement, micronutrient surveillance, and the composition, delivery and complications of (home) parenteral nutrition. We also position the pharmacological adjuncts, culminating in glucagon-like peptide-2 (GLP-2) analogues, within a stepwise strategy to reduce parenteral-support dependence. The goal throughout is a practical, physiology-anchored approach that maximises enteral autonomy and quality of life while preventing the metabolic, hepatic and catheter-related complications of long-term intravenous feeding.
- 27 August 2026
- Published by MDPI AG in Preprints.org
Open AccessDietary and Parenteral Nutritional Management of Short Bowel Syndrome with Intestinal Failure in Adults
Short bowel syndrome (SBS) is the leading cause of chronic intestinal failure in adults, arising when the residual small bowel can no longer absorb the macronutrients, water and electrolytes needed to sustain health without intravenous supplementation. Its management is, at its core, a nutritional problem. This review synthesises current evidence and guideline recommendations on the two pillars of that management: dietary (oral/enteral) therapy and parenteral nutritional support. We frame both around the two variables that dominate clinical behaviour, namely residual intestinal anatomy and the phase of intestinal adaptation, and translate them into anatomy-tailored dietary strategies, rational fluid and electrolyte replacement, micronutrient surveillance, and the composition, delivery and complications of (home) parenteral nutrition. We also position the pharmacological adjuncts, culminating in glucagon-like peptide-2 (GLP-2) analogues, within a stepwise strategy to reduce parenteral-support dependence. The goal throughout is a practical, physiology-anchored approach that maximises enteral autonomy and quality of life while preventing the metabolic, hepatic and catheter-related complications of long-term intravenous feeding.
- Open Access
- 29 July 2026
- Published by Springer Nature in Journal of Ultrasound
- Vol. 29 (4) , 949-961
Intestinal ultrasound in primary intestinal lymphangiectasia (Waldmann’s disease): a PRISMA-ScR scoping review with an illustrative adult case
Primary intestinal lymphangiectasia (PIL; Waldmann’s disease, ORPHA 90362) is a rare protein-losing enteropathy in which dilated intestinal lacteals leak chyle into the gut lumen. Cross-sectional imaging and lymphoscintigraphy have historically dominated assessment, while transabdominal B-mode intestinal ultrasound (IUS)—a cornerstone modality for inflammatory bowel disease—has remained almost unmapped in PIL. We conducted a PRISMA-ScR scoping review (Open Science Framework preregistration gfbc9) of all primary studies reporting transabdominal B-mode IUS in PIL, searching three bibliographic platforms (PubMed/MEDLINE, Ovid Multifile, Scopus) supplemented by forward and backward citation chasing. Studies using only extra-intestinal ultrasound, endoscopic ultrasound, those describing secondary lymphangiectasia or focal lymphangioma, and those using ultrasound only as procedural guidance for lymphangiography were excluded at full-text stage. Fifteen primary studies, published 1986–2026 across thirteen countries, met eligibility (nine paediatric, six adult). All fifteen reported per-patient B-mode IUS findings extractable for synthesis. A consistent sonographic signature emerged: diffuse, regular, slightly hypoechoic small-bowel-wall thickening with preserved five-layer stratification and prominent valvulae conniventes; dilated fluid-filled loops with reduced peristalsis; oedematous mesentery, variable ascites; and characteristically absent mesenteric lymphadenopathy (with two notable exceptions framed only as a research hypothesis). Diagnostic accuracy as a screening tool has been evaluated only in one study ( n = 20: accuracy 80%, 95% CI 56.3–94.3%). We illustrate this signature in a 42-year-old woman with Hennekam syndrome and report quantitative B-mode IUS values as anecdotal single-observation—single sonographer, single device, single fasted time-point, mid-jejunal segment to motivate, prospective standardisation.
- 29 July 2026
- Published by Springer Nature in Journal of Ultrasound
- Vol. 29 (4) , 949-961
Open AccessIntestinal ultrasound in primary intestinal lymphangiectasia (Waldmann’s disease): a PRISMA-ScR scoping review with an illustrative adult case
Primary intestinal lymphangiectasia (PIL; Waldmann’s disease, ORPHA 90362) is a rare protein-losing enteropathy in which dilated intestinal lacteals leak chyle into the gut lumen. Cross-sectional imaging and lymphoscintigraphy have historically dominated assessment, while transabdominal B-mode intestinal ultrasound (IUS)—a cornerstone modality for inflammatory bowel disease—has remained almost unmapped in PIL. We conducted a PRISMA-ScR scoping review (Open Science Framework preregistration gfbc9) of all primary studies reporting transabdominal B-mode IUS in PIL, searching three bibliographic platforms (PubMed/MEDLINE, Ovid Multifile, Scopus) supplemented by forward and backward citation chasing. Studies using only extra-intestinal ultrasound, endoscopic ultrasound, those describing secondary lymphangiectasia or focal lymphangioma, and those using ultrasound only as procedural guidance for lymphangiography were excluded at full-text stage. Fifteen primary studies, published 1986–2026 across thirteen countries, met eligibility (nine paediatric, six adult). All fifteen reported per-patient B-mode IUS findings extractable for synthesis. A consistent sonographic signature emerged: diffuse, regular, slightly hypoechoic small-bowel-wall thickening with preserved five-layer stratification and prominent valvulae conniventes; dilated fluid-filled loops with reduced peristalsis; oedematous mesentery, variable ascites; and characteristically absent mesenteric lymphadenopathy (with two notable exceptions framed only as a research hypothesis). Diagnostic accuracy as a screening tool has been evaluated only in one study ( n = 20: accuracy 80%, 95% CI 56.3–94.3%). We illustrate this signature in a 42-year-old woman with Hennekam syndrome and report quantitative B-mode IUS values as anecdotal single-observation—single sonographer, single device, single fasted time-point, mid-jejunal segment to motivate, prospective standardisation.
- Open Access
- 7 July 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (7) , 1045
Gut Microbiota in NSAID Enteropathy: Current Evidence and Future Perspectives for Therapeutic Strategies
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed worldwide for their analgesic, antipyretic, and anti-inflammatory properties. However, their long-term use is associated with substantial gastrointestinal (GI) toxicity. Although upper GI injury has traditionally received greater attention, NSAID-induced enteropathy is now increasingly recognized as a common yet underdiagnosed condition. Advances in small-bowel imaging, particularly capsule endoscopy, have demonstrated that mucosal injury of the small intestine occurs in up to 70–80% of chronic NSAID users and may also develop after short-term exposure in otherwise healthy individuals, often without overt clinical symptoms. When symptoms do occur, NSAID-induced enteropathy is characterized by non-specific clinical manifestations and may lead to severe complications in approximately 1% of cases. The pathogenesis of NSAID-induced enteropathy is multifactorial and more complex than that underlying upper GI damage. It involves prostaglandin depletion, increased intestinal permeability, bile acid-mediated toxicity, enterohepatic recirculation of NSAIDs, and, importantly, interactions with the gut microbiota. Concomitant therapies, particularly proton pump inhibitors, may further aggravate small-bowel injury by promoting intestinal dysbiosis. Growing evidence supports a relevant contributory role for the gut microbiota as both a mediator and a modulator of NSAID-induced toxicity, affecting epithelial barrier function, oxidative stress, immune responses, and bile acid metabolism. This review provides an overview of current knowledge of NSAID-induced enteropathy, with a particular emphasis on the microbiota-driven mechanisms underlying mucosal injury. By integrating emerging microbiota-targeted therapeutic approaches, we propose a management algorithm that may help modify disease progression in a condition that remains frequently overlooked in clinical practice.
- 7 July 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (7) , 1045
Open AccessGut Microbiota in NSAID Enteropathy: Current Evidence and Future Perspectives for Therapeutic Strategies
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed worldwide for their analgesic, antipyretic, and anti-inflammatory properties. However, their long-term use is associated with substantial gastrointestinal (GI) toxicity. Although upper GI injury has traditionally received greater attention, NSAID-induced enteropathy is now increasingly recognized as a common yet underdiagnosed condition. Advances in small-bowel imaging, particularly capsule endoscopy, have demonstrated that mucosal injury of the small intestine occurs in up to 70–80% of chronic NSAID users and may also develop after short-term exposure in otherwise healthy individuals, often without overt clinical symptoms. When symptoms do occur, NSAID-induced enteropathy is characterized by non-specific clinical manifestations and may lead to severe complications in approximately 1% of cases. The pathogenesis of NSAID-induced enteropathy is multifactorial and more complex than that underlying upper GI damage. It involves prostaglandin depletion, increased intestinal permeability, bile acid-mediated toxicity, enterohepatic recirculation of NSAIDs, and, importantly, interactions with the gut microbiota. Concomitant therapies, particularly proton pump inhibitors, may further aggravate small-bowel injury by promoting intestinal dysbiosis. Growing evidence supports a relevant contributory role for the gut microbiota as both a mediator and a modulator of NSAID-induced toxicity, affecting epithelial barrier function, oxidative stress, immune responses, and bile acid metabolism. This review provides an overview of current knowledge of NSAID-induced enteropathy, with a particular emphasis on the microbiota-driven mechanisms underlying mucosal injury. By integrating emerging microbiota-targeted therapeutic approaches, we propose a management algorithm that may help modify disease progression in a condition that remains frequently overlooked in clinical practice.
- Open Access
The Evolving Role of Eosinophils in Eosinophilic Esophagitis: Mechanisms, Crosstalk, and Therapeutic Perspectives
Introduction: Eosinophilic esophagitis (EoE) is a chronic immune-mediated esophageal disease characterized by eosinophilic infiltration, epithelial barrier dysfunction, and progressive tissue remodeling. Increasing evidence identifies eosinophils as central drivers of inflammation and fibrosis, linking EoE to type 2 immune responses and allergic disorders. However, the molecular mechanisms underlying eosinophil-mediated esophageal damage and their interaction with gastroesophageal reflux disease (GERD) remain incompletely understood. Material and Methods: A comprehensive narrative review of the current literature was conducted, focusing on studies investigating eosinophil biology, inflammatory signaling pathways, epithelial remodeling, fibrosis, and therapeutic targets in EoE. Clinical, translational, and experimental studies evaluating the association between EoE, GERD, and allergic comorbidities were critically analyzed. Results: Available evidence demonstrates that eosinophils actively contribute to EoE pathogenesis through the release of cytotoxic granule proteins, cytokines, chemokines, and lipid mediators, leading to chronic inflammation and fibrostenotic remodeling. Dysregulation of type 2 cytokines, particularly IL-4, IL-5, and IL-13, plays a pivotal role in disease progression and immune cell recruitment. Significant overlap between EoE and GERD suggests shared inflammatory mechanisms and diagnostic challenges. Furthermore, EoE frequently coexists with systemic allergic diseases, supporting the concept of a broader atopic inflammatory phenotype. Emerging biologic therapies targeting eosinophilic and type 2 inflammatory pathways have shown promising efficacy in reducing symptoms and histologic activity. Conclusions: Eosinophils represent key regulators of EoE pathobiology and constitute promising biomarkers and therapeutic targets. A deeper understanding of eosinophil-driven inflammatory networks may improve diagnostic accuracy, patient stratification, and the development of personalized therapeutic strategies for EoE and related esophageal inflammatory disorders.
Open AccessThe Evolving Role of Eosinophils in Eosinophilic Esophagitis: Mechanisms, Crosstalk, and Therapeutic Perspectives
Introduction: Eosinophilic esophagitis (EoE) is a chronic immune-mediated esophageal disease characterized by eosinophilic infiltration, epithelial barrier dysfunction, and progressive tissue remodeling. Increasing evidence identifies eosinophils as central drivers of inflammation and fibrosis, linking EoE to type 2 immune responses and allergic disorders. However, the molecular mechanisms underlying eosinophil-mediated esophageal damage and their interaction with gastroesophageal reflux disease (GERD) remain incompletely understood. Material and Methods: A comprehensive narrative review of the current literature was conducted, focusing on studies investigating eosinophil biology, inflammatory signaling pathways, epithelial remodeling, fibrosis, and therapeutic targets in EoE. Clinical, translational, and experimental studies evaluating the association between EoE, GERD, and allergic comorbidities were critically analyzed. Results: Available evidence demonstrates that eosinophils actively contribute to EoE pathogenesis through the release of cytotoxic granule proteins, cytokines, chemokines, and lipid mediators, leading to chronic inflammation and fibrostenotic remodeling. Dysregulation of type 2 cytokines, particularly IL-4, IL-5, and IL-13, plays a pivotal role in disease progression and immune cell recruitment. Significant overlap between EoE and GERD suggests shared inflammatory mechanisms and diagnostic challenges. Furthermore, EoE frequently coexists with systemic allergic diseases, supporting the concept of a broader atopic inflammatory phenotype. Emerging biologic therapies targeting eosinophilic and type 2 inflammatory pathways have shown promising efficacy in reducing symptoms and histologic activity. Conclusions: Eosinophils represent key regulators of EoE pathobiology and constitute promising biomarkers and therapeutic targets. A deeper understanding of eosinophil-driven inflammatory networks may improve diagnostic accuracy, patient stratification, and the development of personalized therapeutic strategies for EoE and related esophageal inflammatory disorders.